Detalles de la búsqueda
1.
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet
; 385(9983): 2153-61, 2015 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25743173
2.
Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
Lipids Health Dis
; 15(1): 116, 2016 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27405296
3.
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
J Lipid Res
; 54(2): 467-72, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23172660
4.
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
N Engl J Med
; 363(25): 2406-15, 2010 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21082868
5.
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.
J Am Coll Cardiol
; 81(16): 1553-1564, 2023 04 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36889610
6.
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
Am Heart J
; 162(4): 708-16, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21982664
7.
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Am Heart J
; 157(2): 352-360.e2, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19185645
8.
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
Am Heart J
; 158(4): 513-519.e3, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19781408
9.
Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
Clin Ther
; 31(1): 115-22, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19243712
10.
Effects of sources of variability on sample sizes required for RCTs, applied to trials of lipid-altering therapies on carotid artery intima-media thickness.
Clin Trials
; 6(4): 305-19, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19667027
11.
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
Am J Cardiol
; 101(5): 625-30, 2008 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18308010
12.
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
Am Heart J
; 153(2): 335.e1-8, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17239698
13.
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Am J Cardiol
; 119(3): 388-396, 2017 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27956003
14.
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
J Am Coll Cardiol
; 69(8): 911-921, 2017 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28231942
15.
A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Am J Cardiol
; 120(4): 569-576, 2017 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28624096
16.
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Clin Ther
; 28(6): 849-59, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16860168
17.
Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
Curr Med Res Opin
; 22(5): 823-35, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16709304
18.
Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients.
Atherosclerosis
; 179(2): 361-7, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15777554
19.
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).
Diabetes Care
; 27(7): 1735-40, 2004 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15220255
20.
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
MedGenMed
; 7(3): 3, 2005 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-16369229